Pulmonary alveolar proteinosis.

Area of Science:

• Pulmonology
• Immunology
• Rare Diseases

Background:

• Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by surfactant accumulation in alveoli.
• Impaired surfactant metabolism is a key feature, leading to proteinaceous material buildup.
• The disease is predominantly autoimmune, linked to granulocyte macrophage colony-stimulating factor (GM-CSF) antibodies, but can also be congenital or secondary.

Purpose of the Study:

• To elucidate the pathogenetic mechanisms of pulmonary alveolar proteinosis.
• To highlight diagnostic features and current therapeutic strategies.
• To explore novel treatment approaches for this rare condition.

Main Methods:

• Utilized insights from animal models to identify GM-CSF antibodies as a pathogenic factor.
• Reviewed characteristic high-resolution computed tomography (CT) findings, such as crazy-paving patterns.
• Described diagnostic lung biopsy results showing alveolar filling with specific material.

Main Results:

• Identified GM-CSF antibodies as a significant pathogenetic mechanism in autoimmune PAP.
• Highlighted delayed diagnosis due to the disease's indolent course.
• Confirmed whole-lung lavage as a primary therapy for symptomatic patients.

Conclusions:

• Autoimmune PAP, driven by GM-CSF antibodies, is the most common form.
• Whole-lung lavage remains the standard therapy, with exogenous GM-CSF as an alternative.
• Combination therapy of systemic GM-CSF and whole-lung lavage presents a promising novel approach for PAP management.